ACTRN12624000524594招募中1 期
A Double-blind Placebo-controlled Phase 1 Study to Evaluate the Safety and Efficacy of MB-001 in Single and Multiple Ascending Doses in Healthy Human Participants
Mage Biologics0 个研究点目标入组 48 人开始时间: 2024年4月26日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 48
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 65 Years（—）
- 性别
- All
入选标准
- •1. Written informed consent prior to the conduct of any study-related assessment.
- •2. Adults aged 18 to 65 years, inclusive, at the time of signing the informed consent form (ICF).
- •3. Body mass index of 18 to 30 kg/m2, inclusive, at Screening.
- •4. Estimated glomerular filtration rate > 60 mL/min/1.73m2 at screening, calculated using the Chronic Kidney Disease Epidemiology Collaboration formula.
- •5. Participants of childbearing potential, fertile male participants, and the female partners of childbearing potential of fertile male participants, must agree to abstain from sexual intercourse or must agree to use highly effective or acceptable methods of contraception from the first dose of study drug until 28 days after the last dose of study drug.
- •6. Agrees not to donate sperm or ova from first dose of study drug until 90 days or 30 days, respectively, after the last dose of study drug.
- •7. Willing and able to comply with the study requirements, including remaining at the CRU for the in-house portion of study participation.
- •8. Agrees not to smoke, vape, or consume tobacco or other nicotine-containing products, from screening until the end of study participation. This includes the use of nicotine patches.
- •9. Agrees not to consume alcohol from 3 days prior to first dose of study drug until the end of the in-house portion of study participation.
- •10. Agrees not to consume products containing caffeine or other xanthines from 2 days prior to first dose of study drug until the end of the in-house portion of study participation.
- •11. Is in good health based on medical history, physical examination, vital signs measurements, safety laboratory tests, and electrocardiograms (ECGs) performed at screening.
排除标准
- •1. Has any condition that places the participant at significantly increased risk or may compromise the study objectives.
- •2. Is mentally or legally incapacitated, at screening or expected during the conduct of the study or has a history of a clinically significant psychiatric disorder that would impact study conduct.
- •3. Has a history of lymphoma, leukemia, or any malignant neoplasms or carcinoma in situ within 5 years prior to screening (except successfully treated nonmetastatic cutaneous squamous cell or basal cell carcinoma and/or localized carcinoma in situ of the cervix).
- •4. Regularly consumes more than 2 units of alcoholic beverages per day or more than 14 units per week (1 unit of alcohol equals 1 pint [473 mL] of beer or lager, 1 glass [125 mL] of wine, 25 mL shot of 40% spirit) within 1 month prior to screening.
- •5. Has a history of drug or alcohol abuse (defined by the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition) within 3 months prior to screening.
- •6. Females who are pregnant or lactating.
- •7. For participants of childbearing potential, has a positive pregnancy test at screening or Day -1.
- •8. Has a QTc > 450 msec for male participants or > 470 msec for female participants at screening or Day -1.
- •NOTE: The QTc is the QT interval corrected for heart rate according to Fridericia’s formula
- •(QTcF = QT/(RR^0.33).
- •9. Has any 12-lead ECG finding at screening or prior to first dose of study drug that may, in the opinion of the Investigator, compromise interpretation of ECGs for cardiac safety assessment or complicate interpretation of events that may occur post dose (e.g., QT not accurately measurable, conduction abnormalities).
- •10. Has alanine transaminase or aspartate transaminase levels > 1.5 x upper limit of normal (ULN) at screening or Day -1.
- •11. Has total bilirubin > 1.5 x ULN (isolated bilirubin > 1.5 x ULN is acceptable if total bilirubin is
- •fractionated and direct bilirubin is < 35%) at screening or Day -1.
- •12. Has a current or chronic history of liver disease. This includes, but is not limited to, hepatitis virus infections, drug- or alcohol-related liver disease, non-alcoholic steatohepatitis, autoimmune hepatitis, hemochromatosis, Wilson’s disease, a-1 antitrypsin deficiency, primary biliary cholangitis, primary sclerosing cholangitis, or any other liver disease considered clinically significant by the Investigator.
- •13. Has known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
- •14. Has a positive test for the presence of HIV, hepatitis C antibody, hepatitis B surface antigen or hepatitis B core antibody at screening or within 3 months prior to first dose of study drug.
- •15. Has had symptomatic herpes zoster within 3 months prior to first dose of study drug.
- •16. Has evidence of active or latent tuberculosis (TB) at screening, as documented by QuantiFERON® TB Gold Plus test.
- •17. Has received treatment with a live, attenuated vaccine within 4 weeks prior to randomization or anticipation of need for such a vaccine during the study period.
- •18. Has a contraindication to blood sampling or is considered to have insufficient peripheral venous access.
- •19. Has donated or lost blood or blood products in volumes of 450 mL or more from 30 days prior to first dose of study drug until the end of study participation.
- •20. Has a history of any known relevant allergy/hypersensitivity or intolerance (including allergy or intolerance to the study me
研究者
相似试验
已完成
不适用
A phase 1 double blind, placebo controlled study of ALX-0141 single dose subcutaneous administration in healthy post-menopausal womeBone loss10005959NL-OMON32748Ablynx N.V.42
已完成
1 期
A clinical phase I study on GIC-1001 in healthy volunteersGastroenterology/pain management/management of visceral pain during sedation-free colonoscopyDigestive SystemISRCTN09480239gIcare Pharma Inc (Canada)80
已完成
不适用
A Phase 1, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses Oral Doses of APX001, to Investigate the Effect of Food on APX001 and to Investigate the Drug-Drug Interaction Potential of APX001Fungal infectionNL-OMON45345Amplyx Pharmaceuticals, Inc.46
招募中
2 期
Relative Evaluation of the benefit of Cilnidipine ON the Nature, Observational Indices, Temperature changes, and overall Effect in secondary Raynaud’s disease (RECONNOITER-1)Cardiovascular - Other cardiovascular diseasesInflammatory and Immune System - Other inflammatory or immune system disordersRaynaud's syndromeACTRN12621000459820AISA Pharma Australia Pty. Ltd.76
进行中（未招募）
1 期
A Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosison-alcoholic Steatohepatitis (NASH) CirrhosisMedDRA version: 20.0Level: LLTClassification code: 10009214Term: Cirrhosis of liver without mention of alcohol Class: 10019805CTIS2024-510627-20-00Madrigal Pharmaceuticals Inc.700